CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection

Immunology

Volumn 108, Issue 1, 2003, Pages 3-9

  Fleuridor, Richardson ^a   Wilson, Brian ^b   Hou, Runhua ^b   Landay, Alan ^a   Kessler, Harold ^a   Al Harthi, Lena ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIGEN P24; CD161 ANTIGEN; CD1D ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; FAS ANTIGEN; HLA DR ANTIGEN; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LYMPHOCYTE CLONE; MONONUCLEAR CELL; NATURAL KILLER CELL; PHENOTYPE; PRIMARY INFECTION; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE; TARGET CELL; VIRION; VIRUS STRAIN;

EID: 0037238537     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01560.x     Document Type: Article

References (40)

1. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21:573.
2. + natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000; 99:229.
3. + NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164:4458.
4. Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188:1521.
5. Gumperz JE, Roy C, Makowska A et al. Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000 February; 12:211.
6. Wilson SB, Kent SC, Horton HF, Hill AA, Bollyky PL, Hafler DA, Strominger JL, Byrne MC. Multiple differences in gene expression in regulatory Valpha 24Jalpha Q T cells from identical twins discordant for type I diabetes. Proc Natl Acad Sci USA 2000; 97:7411.
7. - NKT cells with distinct TCR alpha beta repertoires and differential distribution in lymphoid tissues. J Immunol 2000; 165:2481.
8. Baur N, Nerz G, Nil A, Eichmann K. Expression and selection of productively rearranged TCR beta VDJ genes are sequentially regulated by CD3 signaling in the development of NK1.1 (+) alpha beta T cells. Int Immunol 2001; 13:1031.
9. Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278:1626.
10. Hammond KJ, Pelikan SB, Crowe NY et al. NKT cells are phenotypically and functionally diverse. Eur J Immunol 1999; 29:3768.
11. Bendelac A. Mouse NK1(+) T cells. Curr Opin Immunol 1995; 7:367.
12. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1:521.
13. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001; 167:3114.
14. Nishikawa K, Shibasaki C, Hiratsuka M, Arakawa M, Takahashi K, Takeuchi T. Antitumor spectrum of deoxyspergualin and its lack of cross-resistance to other antitumor agents. J Antibiot (Tokyo) 1991; 44:1101.
15. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8 (+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001; 97:2923.
16. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165:2665.
17. Hong S, Wilson MT, Serizawa I et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:1052.
18. Naumov YN, Bahjat KS, Gausling R et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001; 98:13838.
19. Sharif S, Arreaza GA, Zucker P et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001; 7: 1057.
20. Wilson SB, Kent SC, Patton KT et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391:177.
21. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001; 13:458.
22. Behar SM, Dascher CC, Grusby MJ, Wang CR, Brenner MB. Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis. J Exp Med 1999: 1891973.
23. Apostolou I, Takahama Y, Belmant C et al. Murine natural killer T (NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci USA 1999; 96:5141.
24. Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guerin. Eur J Immunol 1999; 29:650.
25. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192:921.
26. Sugawara I. Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens. Microbes Infect 2000; 2:1257.
27. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M et al. Alpha-galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000; 97:8461.
28. Nakano Y, Hisaeda H, Sakai T, Zhang M, Maekawa Y, Zhang T, Himeno K. Role of innate immune cells in protection against Toxoplasma gondii at inflamed site. J Med Invest 2001; 48:73.
29. Ishikawa H, Hisaeda H, Taniguchi M et al. CD4 (+) v (alpha) 14 NKT cells play a crucial role in an early stage of protective immunity against infection with Leishmania major. Int Immunol 2000; 12:1267.
30. Lim TS, Murphy JW. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun 1980; 30:5.
31. Kawakami K, Kinjo Y, Uezu K et al. Monocyte chemoattractant protein-1-dependent increase of V alpha 14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol 2001; 167:6525.
32. +NKT cells during HIV type 1 infection. Immunol 2002; 168:1490.
33. Yang Y, Bao M, Yoon JW. Intrinsic defects in the T-cell lineage results in natural killer T-cell deficiency and the development of diabetes in the nonobese diabetic mouse. Diabetes 2001; 50:2691.
34. Bastiani Lallos L, Cecilia D, Fenyo EM, Laal S, Zolla-Pazner S. HIV phenotype correlates with the relative amounts of lymphocyte function-related molecule 1 (LFA-1) and major histocompatibility complex (MHC) class II in the virion envelope. AIDS 2000 July 28; 14:1523.
35. Cecilia D, Kewa I, Ramani VN et al. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 1998; 72:6988.
36. + T cells. Immunology 2001; 103:270.
37. Kitchen SG, Korin YD, Roth MD, Landay A, Zack JA. Costimulation of naive CD8 (+) lymphocytes induces CD4 expression and allows human immunodeficiency virus type 1 infection. J Virol 1998; 72:9054.
38. + T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc Natl Acad Sci USA 1998; 95:3111.
39. Steffens CM, Smith KY, Landay A, Shott S, Truckenbrod A, Russert M, Al-Harthi L. T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals. AIDS 2001: 15, 1757.
40. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med 2002; 195:869.